Top

Journal of Endocrinological Investigation

Published in:

01-02-2014 | Original Article

Serum galectin-3 levels in women with PCOS

Authors: H. Yilmaz, H. T. Celik, O. Ozdemir, D. Kalkan, M. Namuslu, S. Abusoglu, C. R. Atalay, R. Yigitoglu

Published in: Journal of Endocrinological Investigation | Issue 2/2014

Abstract

Aim

Galectin-3 (Gal-3) plays a role in modulation of adiposity, glucose hemostasis and inflammation. The association between Gal-3 and the polycystic ovary syndrome (PCOS), is not investigated. We aimed to evaluate galectin-3 levels in serum and their relation with hyperandrogenism and insulin resistance (IR) in women with polycystic ovary syndrome (PCOS) and in control subjects.

Materials and methods

56 women with PCOS were enrolled along with a control group of 41 healthy women, matched for age and body mass index. We measured hormonal and metabolic parameters, as well as the serum galectin-3 concentration of each participant. We estimated the IR according to the homeostasis model assessment-insulin resistance (HOMA-IR).

Results

Women with PCOS had higher levels of serum Gal-3 compared to healthy individuals (3,588.77 ± 1,566.94 vs 2,491.33 ± 812.04, P < 0.001). Serum Gal-3 levels were correlated with progesterone (r = 0.241, P = 0.025), hirsutism score (r = 0.296, P = 0.006), insulin (r = 0.479, P = 0.028), HOMA-IR (r = 0.514, P = 0.017), dehydroepiandrosterone sulfate (r = 0.246, P = 0.022), testosterone (r = 0.252, P = 0.019), and free testosterone (r = 0.306, P = 0.004).

Conclusion

Galectin-3 levels are higher in patients with PCOS, and there is a positive correlation between galectin-3 level and IR, androgen levels and hirsutismus scores. Gal-3 may be a new mediator of PCOS via IR, hyperandrogenism.

Nisenblat V, Norman RJ (2009) Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes 16(3):224–231PubMedCrossRef

Marx TL, Mehta AE (2003) Polycystic ovary syndrome: pathogenesis and treatment over the short and long term. Cleve Clin J Med 70(1):31–41PubMed

Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Polycystic ovary syndrome. Lancet 370:685–697PubMedCrossRef

Talbott E, Guzick D, Clerici A et al (1995) Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15:821–826PubMedCrossRef

Wild RA (1995) Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med 98:27S–32SPubMedCrossRef

Duleba AJ, Dokras A (2012) Is PCOS an inflammatory process? Fertil Steril 97(1):7–12PubMedCentralPubMed

El-Mesallamy HO, Abd El-Razek RS, El-Refaie TA (2013) Circulating high-sensitivity C-reactive protein and soluble CD40 ligand are inter-related in a cohort of women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 168(2):178–182PubMedCrossRef

Repaci A, Gambineri A, Pasquali R (2011) The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol 335(1):30–41PubMedCrossRef

Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141–146PubMedCrossRef

10.

Azevedo MF, Costa EC, Oliveira AIN, Silva IBO, Marinho JCDB, Rodrigues JAM et al (2011) Elevated blood pressure in women with polycystic ovary syndrome: prevalence and associated risk factors. Rev Bras Ginecol Obstet 33(1):31–36PubMed

11.

Kelly CJ, Speirs A, Gould GW et al (2002) Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 87:742–746PubMedCrossRef

12.

Henderson NC, Sethi T (2009) The regulation of inflammation by galectin-3. Immunol Rev 230(1):160–171PubMedCrossRef

13.

Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D (2012) Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60(14):1249–1256PubMedCentralPubMedCrossRef

14.

de Boer RA, van Veldhuisen DJ, Gansevoort RT et al (2012) The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 272:55–64PubMedCrossRef

15.

Yan Y, Lang B, Vemuganti R et al (2009) Galectin-3 mediates post-ischemic tissue remodeling. Brain Res 1288:116–124PubMedCrossRef

16.

Arar C, Gaudin JC, Capron L, Legrand A (1998) Galectin-3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells. FEBS Lett 430:307–311PubMedCrossRef

17.

Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, D’Angelo A, Schirinzi S, Totaro R, Falcone R, Bondesan M, Pelissero G (2011) Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol 24(4):905–913PubMed

18.

Nachtigal M, Ghaffar A, Mayer EP (2008) Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol 172(1):247–255PubMedCrossRef

19.

Mensah-Brown EP (2009) Al Rabesi Z, Shahin A, Al Shamsi M, Arsenijevic N, Hsu DK, Liu FT, Lukic ML. Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Clin Immunol 130(1):83–88PubMedCrossRef

20.

Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, Schnitzbauer A, Schäffler A, Aslanidis C, Schölmerich J, Buechler C (2010) Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 95(3):1404–1411PubMedCrossRef

21.

Pejnovic NN, Pantic JM, Jovanovic IP, Radosavljevic GD, Milovanovic MZ, Nikolic IG, Zdravkovic NS, Djukic AL, Arsenijevic NN, Lukic ML (2013) Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Diabetes 62(6):1932–1944PubMedCrossRef

22.

Nio J, Iwanaga T (2007) Galectins in the mouse ovary: concomitant expression of galectin-3 and progesterone degradation enzyme (20alpha-HSD) in the corpus luteum. J Histochem Cytochem 55(5):423–432PubMedCrossRef

23.

Kim H, Lee J, Hyun JW, Park JW, Joo HG, Shin T (2007) Expression and immunohistochemical localization of galectin-3 invarious mouse tissues. Cell Biol Int 31:655–662PubMedCrossRef

24.

Kim M, Kim S, Kim H, Kim H, Joo HG, Shin T (2008) Immunohistochemical localization of galectin-3 in the reproductive organs of the cow. Acta Histochem 110(6):473–480PubMedCrossRef

25.

Zaia Povegliano L, Oshima CT, de Oliveira Lima F, Andrade Scherholz PL, Manoukian Forones N (2011) Immunoexpression of galectin-3 in colorectal cancer and its relationship with survival. J Gastrointest Cancer 42(4):217–221PubMedCrossRef

26.

Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM (2010) Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 176(5):2067–2081PubMedCrossRef

27.

Miyazaki J, Hokari R, Kato S, Tsuzuki Y, Kawaguchi A, Nagao S, Itoh K, Miura S (2002) Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep 9:1307–1312PubMed

28.

Saussez S, Camby I, Toubeau G, Kiss R (2007) Galectins as modulators of tumor progression in head and neck squamous cell carcinomas. Head Neck 9:874–884CrossRef

29.

Pang J, Rhodes DH, Pini M, Akasheh RT, Castellanos KJ, Cabay RJ, Cooper D, Perretti M, Fantuzzi G (2013) Increased adiposity, dysregulated glucose metabolism and systemic inflammation in galectin-3 KO mice. PLoS One 8(2):e57915PubMedCentralPubMedCrossRef

30.

Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G (2005) Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 62(1):37–43CrossRef

31.

Christakou C, Economou F, Livadas S, Piperi C, Adamopoulos C, Marinakis E, Jdiamanti-Kandarakis E (2011) Strong and positive association of endothelin-1 with AGEs in PCOS: a causal relationship or a bystander? Hormones (Athens) 10(4):292–297CrossRef

32.

Iacobini C, Menini S, Oddi G, Ricci C, Amadio L, Pricci F, Olivieri A, Sorcini M, Di Mario U, Pesce C, Pugliese G (2004) Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 18:1773–1775PubMed

33.

Kim MK, Sung CO, Do IG, Jeon HK, Song TJ, Park HS, Lee YY, Kim BG, Lee JW, Bae DS (2011) Overexpression of galectin-3 and its clinical significance in ovarian carcinoma. Int J Clin Oncol 16(4):352–358PubMedCrossRef

34.

Tilly JL (1996) Apoptosis and ovarian function. Rev Reprod 1:162–172PubMedCrossRef

35.

Nakahara S, Oka N, Raz A (2005) On the role of galectin-3 in cancer apoptosis. Apoptosis 10(2):267–275PubMedCrossRef

Title: Serum galectin-3 levels in women with PCOS
Authors: H. Yilmaz
H. T. Celik
O. Ozdemir
D. Kalkan
M. Namuslu
S. Abusoglu
C. R. Atalay
R. Yigitoglu
Publication date: 01-02-2014
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 2/2014
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-013-0032-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aim

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2014

Serum interferon gamma concentration is associated with bone mineral density in overweight boys

Phenotypical and genotypical expression of Wolfram syndrome in 12 patients from a Sicilian district where this syndrome might not be so infrequent as generally expected

Is routine endocrine evaluation necessary after paediatric traumatic brain injury?

Frequency and effect on serum TSH of phosphodiesterase 8B (PDE8B) gene polymorphisms in patients with sporadic nonautoimmune subclinical hypothyroidism

Pre-treatment circulating leptin/ghrelin ratio as a non-invasive marker to identify patients likely to regain the lost weight after an energy restriction treatment

Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials